NCT05307926View on ClinicalTrials.gov

Postoperative Adjuvant Therapy of HCC Based on PD-1

CompletedOBSERVATIONAL
Enrollment

573

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

July 30, 2022

Study Completion Date

August 20, 2022

Conditions
Hepatocellular CarcinomaRFS
Interventions
DRUG

PD-1 inhibitors

For patients with PVTT, they received adjuvant therapy of PD1 (200mg intravenously every 3 weeks for a total of 18cycles) plus Lenvatinib (8mg orally once a day for 1 year) 2-4 weeks after surgery; for patients with other high-risk factors for recurrence, they PD-1(200mg intravenously every 3 weeks for a total of 9cycles) monotherapy 2-4 weeks after surgery.

PROCEDURE

TACE

Patients with high-risk factors for recurrence received 1 TACE about a month after surgery.

Trial Locations (1)

430030

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Chen Xiaoping

OTHER

NCT05307926 - Postoperative Adjuvant Therapy of HCC Based on PD-1 | Biotech Hunter | Biotech Hunter